Abstracts tagged "genomics"

Abstract Number: 0565 • ACR Convergence 2022
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics
Juan Vargas¹, Nirmal Banda², Ian Mantel³, Anna Jonsson⁴, Kevin Wei⁵, Deepak Rao⁴, Susan Goodman⁶, Kevin D Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri⁴, Accelerating Medicines Partnership RA/SLE⁴, Michael Holers², Laura Donlin⁶ and Fan Zhang⁸, ¹School Public Health Biostatistics Department, Aurora, CO, ²Department of Medicine Division of Rheumatology, Aurora, CO, ³Weill Cornell Medicine, New York, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁸University of Colorado, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune arthritis pathogenesis. In patients…
Abstract Number: 1663 • ACR Convergence 2022
Age-Dependent Expansion and Activation of Disease-Associated Microglia in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Caroline Shah¹, Miranda Gurra¹, Yidan Wang¹, Deborah Winter² and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multipe end organs, including the brain. Despite a prevalence of over 50% in…
Abstract Number: 0603 • ACR Convergence 2022
Survivin-dependent Regulation of Bivalent Chromatin and Its Relevance for Adaptive Immunity
Venkataragavan Chandrasekaran¹, Nina Oparina², Karin Andersson², Malin Erlandsson², Maria-Jose Garcia-Bonete³, Maja Jensen⁴, Gergely Katona⁵ and Maria Bokarewa⁶, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Chemistry and Molecular Biology, Gothenburg, Sweden, ⁵Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Bivalent chromatin (BvCR) is characterized by simultaneous binding of active and repressive modifications to the histone H3 proteins. Influencing expression of the genes, BvCR…
Abstract Number: 1666 • ACR Convergence 2022
Differentiation of Injury-associated Macrophages in Lupus Kidneys Is Conserved in Humans and Lupus Mouse Models
Paul Hoover¹, David Lieb², Stephen Li², Chirag Raparia³, Accelerating Medicines Partnership SLE/RA⁴, Arnon Arazi⁵, Nir Hacohen² and Anne Davidson⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY, ⁴NIH, Bethesda, MD, ⁵Feinstein Institutes for Medical Research, Melrose, MA, ⁶Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Infiltrating monocytes acquire functions that support kidney remodeling in response to tissue damage in lupus nephritis. This process of monocyte differentiation has been difficult…
Abstract Number: 0643 • ACR Convergence 2022
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Mary Horton¹, Joanne Nitithalm², Kimberly Taylor³, Laura Trupin⁴, Patricia Katz⁵, Jinoos Yazdany⁶, Maria Dall'Era⁷, Lisa Barcellos⁸, Lindsey Criswell⁹ and Cristina M Lanata¹⁰, ¹NIH/NHGRI, Oakland, CA, ²NIH/NHGRI, Bethesda, MD, ³University of Californi, San Francisco, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶UCSF, San Francisco, CA, ⁷University of California, Division of Rheumatology, San Francisco, CA, ⁸School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, ⁹National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁰NIH/NHGRI, Washington, DC
Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The…
Abstract Number: 1678 • ACR Convergence 2022
A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout
Tony Merriman¹, Hirotaka Matsuo², Riku Takei³, Megan Leask³, Ruth Topless¹, Yuya Shirai⁴, Zhiqiang Li⁵, Murray Cadzow¹, Richard Reynolds³, kenneth saag³, Tayaza Fadason⁶, Justin O'Sullivan⁶, Nicola Dalbeth⁶, Lisa Stamp⁷, Abhishek Abhishek⁸, Michael Doherty⁸, Edward Roddy⁹, Lennart Jacobsson¹⁰, Meliha Kapetanovic¹¹, Mariano Andrès¹², Fernando Perez-Ruiz¹³, Rosa Torres Jimenez¹⁴, Timothy Radstake¹⁵, Timothy Jansen¹⁶, Matthijs Janssen¹⁷, Leo Joosten¹⁸, Tania Octavia Crisan¹⁹, Tom Huizinga²⁰, Frederic LIOTE²¹, Pascal Richette²², Thomas Bardin²³, Tristan Pascart²⁴, Geraldine McCarthy²⁵, Blanka Stiburkova²⁶, Anne Tausche²⁷, Till Uhlig²⁸, Veronique Vitart²⁹, Philip Riches²⁹, Stuart Ralston²⁹, Thomas MacDonald³⁰, Akiyoshi Nakayama², Masahiro Nakatochi³¹, Kimiyoshi Ichida³², Tappei Takada³³, Chaeyoung Lee³⁴, Matthew Brown³⁵, Philip Robinson³⁶, Catherine Hill³⁷, Hyon Choi³⁸, Nicholas Sumpter³, Marilyn Merriman³, Amanda Phipps-Green¹, Wenhua Wei¹, Sally McCormick¹, Olle Melander³⁹, René Toes²⁰, Hang-Korng Ea²¹, Fina Kurreeman²⁰, Laura Helbert²⁵, Thibaud Boutin²⁹, Nariyoshi Shinomiya², Linda Bradbury⁴⁰, Russell Buchanan⁴¹, Susan Lester³⁷, Malcolm Smith⁴², Maureen Rischmueller⁴³, On behalf of Japan Gout Genomics Consortium (J-Gout)⁴⁴, On behalf of Japan Multi-Instl Collab Cohort Study (J-MICC)⁴⁵, Eli Stahl⁴⁶, Jeff Miner⁴⁷, Daniel Solomon⁴⁸, Jing Cui⁴⁸, Kathleen Giacomini⁴⁹, Deanna Brackman⁴⁹, Eric Jorgenson⁵⁰, On behalf of 23andMe Research Team⁵¹, Suyash Shringapure⁵¹, Alexander So⁵², Yukinori Okada⁴, Changgui Li⁵, Yongyong Shi⁵³ and Tanya Major¹, ¹University of Otago, Dunedin, New Zealand, ²National Defense Medical College, Saitama, Japan, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Osaka University, Suita, Osaka, Japan, ⁵The Affiliated Hospital of Qingdao University, Qingdao, China, ⁶University of Auckland, Auckland, New Zealand, ⁷University of Otago, Christchurch, New Zealand, ⁸University of Nottingham, Nottingham, United Kingdom, ⁹Keele University, Keele, United Kingdom, ¹⁰Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ¹¹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden, ¹²Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ¹³University of the Basque Country, Barakaldo, Spain, ¹⁴La Paz University Hospital, Madrid, Spain, ¹⁵University Medical College Uthrecht, Utrecht, Netherlands, ¹⁶VieCuri Medical Centre, Venlo, Netherlands, ¹⁷Rijnstate Hospital, Bennekom, Netherlands, ¹⁸Radboudumc, Nijmegen, Netherlands, ¹⁹University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Cluj-Napoca, Romania, ²⁰Leiden University Medical Center, Leiden, Netherlands, ²¹University of Paris, Paris, France, ²²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ²³Hôpital Lariboisiere, Paris, France, ²⁴Lille Catholic University, Lille, France, ²⁵Mater Misericordiae University Hospital, Dublin, Ireland, ²⁶Institute of Rheumatology, Prague, Czech Republic, ²⁷University Clinic 'Carl Gustav Carus' at the Technical University, Dresden, Germany, ²⁸Diakonhjemmet Hospital, Oslo, Norway, ²⁹University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³⁰University of Dundee, Dundee, United Kingdom, ³¹Nagoya University Hospital, Nagoya, Japan, ³²Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ³³University of Tokyo Hospital, Tokyo, Japan, ³⁴Soongsil University, Seoul, Republic of Korea, ³⁵Genomics England, London, United Kingdom, ³⁶University of Queensland, Brisbane, Australia, ³⁷The Queen Elizabeth Hospital, Adelaide, Australia, ³⁸Massachusetts General Hospital, Lexington, MA, ³⁹Lund University, Malmö, Sweden, ⁴⁰Gold Coast University Hospital, Brisbane, Australia, ⁴¹Austin Health, Heidelberg, Australia, ⁴²Flinders Medical Centre, Adelaide, Australia, ⁴³RheumatologySA, Adelaide, Australia, ⁴⁴Japan Gout Genomics Consortium (J-Gout), Saitama, Japan, ⁴⁵Japan Multi-Institutional Collaborative Cohort Study (J-MICC), Nagoya, Japan, ⁴⁶Regeneron, New York, NY, ⁴⁷ViscientBio, San Diego, CA, ⁴⁸Brigham and Women's Hospital, Boston, MA, ⁴⁹University of California San Francisco, San Francisco, CA, ⁵⁰Kaiser Permanente, San Francisco, CA, ⁵¹23andMe, Inc., Sunnyvale, CA, ⁵²University of Lausanne, Lausanne, Switzerland, ⁵³Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Genome-wide association studies (GWAS) in gout have been relatively small (≤13,179 people with gout) and have provided little insight into the progression from hyperuricemia…
Abstract Number: 0774 • ACR Convergence 2022
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Marthe K. Brun¹, Kristin Hammersbøen Bjørlykke², Marte Kathrine Viken³, Grete-Elisabeth Stenvik¹, Rolf Klaasen³, Johanna Elin Gehin³, David Warren³, Joe Sexton¹, Espen Haavardsholm¹, Jørgen Jahnsen², Benedicte Alexandra Lie³, Nils Bolstad³, Kristin Kaasen Jørgensen², Guro Løvik Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Immunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been…
Abstract Number: 1699 • ACR Convergence 2022
Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations
Yidan Wang¹, Miranda Gurra¹, Carla Cuda¹, Hadijat Makinde¹, Shangyang Chen¹, Gaurav Gadhvi¹, Salina Dominguez¹, Caroline Shah¹, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of circulating monocytes – either classical or non-classical monocytes – is not…
Abstract Number: 0867 • ACR Convergence 2022
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
Hiroto Nakano¹, Emily Shuldiner², Anne Hinks³, Marc Sudman⁴, Elaine Remmers⁵, Colleen Satorius⁶, Elizabeth Schmitz¹, Victoria Arthur⁷, Patricia Woo⁸, Alexei Grom⁹, Dirk Foell¹⁰, John Bohnsack¹¹, Marco Gattorno¹², Seza Ozen¹³, Sampath Prahalad¹⁴, Rae Yeung¹⁵, Elizabeth Mellins², Sheila Oliveira¹⁶, Jordi Antón¹⁷, Claudio Len¹⁸, Carol Lake¹⁹, Ly-Lan Bergeron²⁰, Michelle Millwood²¹, Estefania de los santos²¹, Mariana Correia Marques²², Juvenile Arthritis Consortium for the Immunochip²³, The Genomic Ascertainment Cohort Investigators²⁴, INCHARGE Consortium²⁵, Carl Langefeld²⁶, Susan Thompson²⁷, Wendy Thomson²⁸ and Michael Ombrello¹, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Stanford University, Stanford, CA, ³The University of Manchester, Manchester, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶NHGRI, NIH, Bethesda, MD, ⁷Boston Children's Hospital, Boston, MA, ⁸University College London, London, United Kingdom, ⁹Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰University Hospital Münster, Münster, Germany, ¹¹University of Utah, Salt Lake City, UT, ¹²Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹⁶Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, ¹⁸Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁹NIH, Gaithersburg, MD, ²⁰NIH/NIAMS, Vienna, VA, ²¹NIAMS, NIH, Bethesda, MD, ²²National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, ²³Juvenile Arthritis Consortium for the Immunochip, Bethesda, MD, ²⁴The Genomic Ascertainment Cohort Investigators, Bethesda, MD, ²⁵International Childhood Arthritis Genetics Consortium, Bethesda, MD, ²⁶Wake Forest School of Medicine, Winston Salem, NC, ²⁷Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ²⁸Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare inflammatory disease that causes spiking fever, skin rash, chronic arthritis, and inflammation of the heart and…
Abstract Number: 1727 • ACR Convergence 2022
BATF Represses BIM Expression to Sustain the T Cell Anergy Program
Philip Titcombe, Milagros Silva-Morales, Na Zhang and Daniel Mueller, University of Minnesota, Minneapolis, MN
Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can…
Abstract Number: 1110 • ACR Convergence 2022
Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition
Ingrid Lindquist¹, James T. Rosenbaum² and Marcia Friedman³, ¹Oregon Health and Science University, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR, ³Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR
Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
Abstract Number: 1731 • ACR Convergence 2022
Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients
Urvashi Kaundal¹, Chloe Borden¹, Cihan Oguz², Jinghua Lu², Emilee Stenson¹, Ami Shah³, Maureen Mayes⁴, Ayo Doumatey⁵, Amy Bentley⁵, Daniel Shriner⁵, Robyn Domsic⁶, Thomas Medsger⁷, Paula Ramos⁸, Richard Silver⁸, Virginia Steen⁹, John Varga¹⁰, Vivien Hsu¹¹, Lesley Ann Saketkoo¹², Elena Schiopu¹³, Dinesh Khanna¹⁴, Jessica Gordon¹⁵, Lindsey Criswell¹⁶, Heather Gladue¹⁷, Chris Derk¹⁸, Elana Bernstein¹⁹, S. Louis Bridges, Jr.¹⁵, Victoria Shanmugam²⁰, Lorinda Chung²¹, Suzanne Kafaja²², Reem Jan²³, Marcin Trojanowski²⁴, Avram Goldberg²⁵, Benjamin Korman²⁶, Settara Chandrasekharappa⁵, Faiza Naz²⁷, Stefania Dell'Orso¹, Adebowale Adeyemo⁵, Charles Rotimi⁵, Elaine Remmers⁵, Francesco Boin²⁸, Fredrick Wigley²⁹, Peter Sun², Daniel Kastner⁵ and Pravitt Gourh³⁰, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rutgers-RWJ Medical School, South Plainfield, NJ, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Michigan Medicine, Ann Arbor, MI, ¹⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁷Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Columbia University, New York, NY, ²⁰George Washington University, Great Falls, VA, ²¹Stanford University, Stanford, CA, ²²UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²³University of Chicago, Chicago, IL, ²⁴Boston University School of Medicine, Boston, MA, ²⁵NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁶University of Rochester, Rochester, NY, ²⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²⁸Cedars-Sinai Medical Center, Los Angeles, CA, ²⁹Johns Hopkins University, Baltimore, MD, ³⁰National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibrotic disorder that disproportionately affects African Americans (AA). Previous work from our lab and others has suggested a…
Abstract Number: 1118 • ACR Convergence 2022
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
Laurel Woodridge¹, Elvira Chocano Navarro², George Robinson¹, Paul Ashford¹, Kirsty Waddington³, Anisur Rahman⁴, Christine Orengo⁵, Ines Pineda-Torra⁶ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²VIHR, Barcelona, Spain, ³University College London (alumni), London, United Kingdom, ⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵ISMB / UCL, London, United Kingdom, ⁶Cabimer, Sevilla, Spain
Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
Abstract Number: 1734 • ACR Convergence 2022
Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics
Ananth Aditya Jupudi¹, Michelle Joachims¹, Christina Lawrence¹, Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Astrid Rasmussen¹, Lida Radfar², Kiely Grundahl¹, R. Hal Scofield², Judith James¹, Joel Guthridge¹, Christopher Lessard¹, Linda F. Thompson¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic rheumatic autoimmune disorder that primarily targets the lacrimal and salivary glands (SG) resulting in dry eyes and dry…
Abstract Number: 1119 • ACR Convergence 2022
Investigating Macrophage Heterogeneity in the Esophagus and Lungs of SSc Patients
Hadijat Makinde¹, Carla Cuda¹, Miranda Gurra¹, Mary Carns², Kathleen Aren², Gaurav Gadhvi¹, Salina Dominguez¹, Jane Dematte³, Darren Brenner⁴, John Pandolfino⁵, G. R. Scott Budinger⁴, Deborah Winter⁶ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Division of Rheumatology, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Feinberg School of Medicine, Wilmette, IL, ⁶Northwestern University, Skokie, IL
Background/Purpose: Our group has made important contributions to an emerging understanding of monocytes and macrophages as central to SSc pathogenesis. There are numerous studies that…

« Previous Page
1
…
6
7
8
9
10
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.